idrx.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $242.24MM
IDRx is a clinical-stage biopharmaceutical company that offers precision therapies to patients with gastrointestinal stromal tumors (GIST). Their pipeline includes small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, designed to target genetic drivers and drug-resistant mutations in GIST. IDRx aims to explore the potential of highly potent and selective therapies to address treatment limitations in precision cancer medicine. This company was founded by Alexis Borisy, Ben Auspitz, George Demetri MD, Nicholas Lydon Ph.D, and Robert Forrester in 2021 and is headquartered in Plymouth, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/07/2024 | Series B | $120.24MM | $xx.xx | $414.65MM | RA Capital Management, Commodore Capital, Blackstone, Rock Springs Capital, Andreessen Horowitz, Forge Life Science Partners, Nick Lydon, Merck, Nextech Invest | |
Price per Share
$xx.xx
Shares Outstanding
18,667,528
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
RA Capital Management, Commodore Capital, Blackstone, Rock Springs Capital, Andreessen Horowitz, Forge Life Science Partners, Nick Lydon, Merck, Nextech Invest
|
||||||
08/02/2022 | Series A-2 | $16.19MM | $xx.xx | $309.5MM | Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines | |
Price per Share
$xx.xx
Shares Outstanding
2,947,184
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines
|
||||||
08/02/2022 | Series A-1 | $105.81MM | $xx.xx | $309.5MM | Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines | |
Price per Share
$xx.xx
Shares Outstanding
17,333,480
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines
|